Dashboard
Manage Tickers

NVSNOVARTIS AG

NYSE novartis.com


$ 115.65 $ -0.06 (-0.05 %)    

Friday, 13-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 115.66
$ 115.59 x 100
-- x --
-- - --
$ 88.80 - $ 120.92
1,866,053
na
236.41B
$ 0.57
$ 15.92
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-novartis-analyst-is-no-longer-bullish-here-are-top-downgrades-for-wednesday
This Novartis Analyst Is No Longer Bullish...
09/11/2024 16:13:54

dominos-pizza-to-510-here-are-10-top-analyst-forecasts-for-wednesday
Domino's Pizza To $510? Here Are 10 Top An...
09/11/2024 13:08:03

b-of-a-securities-downgrades-novartis-to-neutral-lowers-price-target-to-130
B of A Securities Downgrades Novartis to N...
09/11/2024 10:29:36

B of A Securities analyst Graham Perry downgrades Novartis (NYSE:NVS) from Buy to Neutral and lowers the price target from $...

enliven-therapeutics-leukemia-candidate-could-challenge-pfizer-astrazeneca-in-broader-target-market-analyst
Enliven Therapeutics' Leukemia Candidate C...
09/09/2024 18:05:21

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwr...

goldman-sachs-shifts-stance-on-novartis-cites-lack-of-near-term-catalysts
Goldman Sachs Shifts Stance On Novartis, C...
09/05/2024 18:34:15

Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential.

sp-global-to-rally-around-10-here-are-10-top-analyst-forecasts-for-thursday
S&P Global To Rally Around 10%? Here Are 1...
09/05/2024 12:19:41

Core News & Articles
Voyager Therapeutics Announces Novartis Li...
09/05/2024 12:04:45

goldman-sachs-downgrades-novartis-to-neutral-raises-price-target-to-121
Goldman Sachs Downgrades Novartis to Neutr...
09/05/2024 10:49:10

Goldman Sachs analyst James Quigley downgrades Novartis (NYSE:NVS) from Buy to Neutral and raises the price target from $119...

despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs
Despite Medicare Negotiations, Americans M...
09/03/2024 19:12:09

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...

jefferies-downgrades-novartis-to-hold
Jefferies Downgrades Novartis to Hold
09/03/2024 12:12:34

Jefferies analyst Peter Welford downgrades Novartis (NYSE:NVS) from Buy to Hold.

novartis-cholesterol-lowering-drug-shows-encouraging-outcome-in-late-stage-study
Novartis' Cholesterol-Lowering Drug Shows ...
08/28/2024 13:33:36

Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate AS...

novartis-pharma-ag-a-subsidiary-of-novartis-inked-a-exclusive-global-licensing-agreement-and-strategic-collaboration-with-lindy-biosciences-for-multi-target-drug-delivery-innovation
Novartis Pharma AG, A Subsidiary Of Novart...
08/28/2024 11:00:01

novartis-phase-3-v-mono-study-for-twice-yearly-leqvio-inclisiran-met-its-primary-endpoints-showing-leqvio-monotherapy-lowered-low-density-lipoprotein-cholesterol-versus-placebo-and-ezetimibe-in-patients-who-were-at-low-or-moderate-risk-of-developing-atherosclerotic-cardiovascular-disease-and-not-receiving-lipid-lowering-therapy
Novartis' Phase 3 V MONO Study For Twice-y...
08/28/2024 10:13:50

siemens-healthineers-to-buy-novartis-diagnostics-to-bolster-cancer-scan-business-in-220m-deal
Siemens Healthineers To Buy Novartis Diagn...
08/26/2024 12:54:18

Siemens Healthineers to acquire Novartis' diagnostics division for over €200M, securing a vital supply of radioactive chemi...

judge-rules-against-novartis-effort-to-halt-generic-launch-of-its-top-selling-heart-disease-drug
Judge Rules Against Novartis' Effort To Ha...
08/13/2024 14:32:11

Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-s...

fda-approves-expanded-use-of-novartis-rare-disease-drug-fabhalta-for-kidney-disease
FDA Approves Expanded Use Of Novartis' Rar...
08/08/2024 13:52:47

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropat...

us-fda-approves-novartis-fabhalta-for-reducing-proteinuria-in-adults-with-primary-immunoglobulin-a-nephropathy-igan
US FDA Approves Novartis' Fabhalta For Red...
08/07/2024 18:22:21

- Reuters 

novartis-and-viatris-sued-over-unlawful-use-of-hela-cells-used-for-cancer-treatment-drugs
Novartis And Viatris Sued Over Unlawful Us...
08/06/2024 17:48:49

Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks prof...

novartis-scemblix-granted-fda-priority-review-for-the-treatment-of-adults-with-newly-diagnosed-cml
Novartis Scemblix Granted FDA Priority Rev...
07/29/2024 16:10:34

https://www.novartis.com/news/media-releases/novartis-scemblix-granted-fda-priority-review-treatment-adults-newly-diagnosed-cml...

watching-novartis-traders-circulating-the-co-lost-a-ruling-from-fda-allowing-for-generic-ernestro
Watching Novartis; Traders Circulating The...
07/24/2024 19:44:40

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION